Improved survival rate in T-cell depleted haploidentical hematopoietic cell transplantation over the last 15 years at a single institutionArticleT-cell depletion of an HLA-haploidentical (haplo) graft is often used to reduce the risk of graft-versus-host disease (GVHD), but the lack of donor T...
成人T细胞白血病/淋巴瘤(adult T-cell leukemia/lymphoma, ATL)是一种高度侵袭性的T细胞恶性肿瘤,常伴有数十年无症状的慢性人类T淋巴细胞病毒1型(humanT-lymphotropic virus type 1, HTLV-1)感染,常发生于在儿童时期通过母乳喂养获得HTLV-1的携带者。HTLV-1在世...
Adult T-cell leukemia/lymphoma (ATL) is a T-cell malignancy caused by infection of human T-cell leukemia virus type 1 (HTLV-1) with CD4+T cells1. The main route of infection is mother-to-child transmission via breast milk, and it is estimated that there are approximately 5–10 million...
rising cancer diagnosis and treatment awareness campaign to increase the survival rate of cancer patients is again spurring the acute lymphoblastic leukemia (T-ALL
T cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy arising from aberrant proliferation of immature T cell progenitors and accounts for about 15% of pediatric ALL cases1. The current risk-adapted, multiagent chemotherapeutic regimen has led to an overall survival rate exceeding ...
T幼淋巴细胞白血病(T-cell prolymphocytic leukemia, T-PLL)是一种罕见的、临床病程异质性的成熟T细胞肿瘤。随着一些新治疗方案的出现,可能会改变T-PLL患者的临床管理,因此需要制定T-PLL的共识指南以更好地设计并实施临床试验。T幼淋巴细胞白血病国际工作组...
在总生存率(Overall Survival Rate,OS)指标上,CAR-T疗法组和化疗组的12个月的总生存率分别为60.9%和10.1%,CAR-T组是化疗组的6倍! CAR-T疗法到底是什么呢? CAR-T疗法全称是Chimeric Antigen Receptor T-Cell Immunotherapy,即嵌合抗原受体T细胞免疫疗法。其主要过程如下图: ...
the survival rate of mice declined, highlighting the potential of drugs targeting CCL2 in the treatment of solid tumors [111]. Foster et al. designed a GD2-specific CAR-T cell expressing CCR2b using a GD2-targeting CAR for neuroblastoma. These CAR-T cells, which modulate the CCL2/CCR2 ax...
48. The decreased immune cell infiltration may enable tumor cells to evade Immunosurveillance and promote cancer development. This phenomenon may account for the notably lower survival rate of high-risk LUAD patients. Our findings revealed that immune checkpoint-related genes (CTLA4, ROS1, ALK, ...
Survival benefit was highly significant also for BV173 mice treated with T1 cells (Fig. 3e), but several of these mice eventually succumbed to tumor, consistent with the lower peptide sensitivity for T1 as compared with T3. Fig. 3: T1 and T3 cells efficiently kill leukemia cells in vivo....